Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study.

Trial Profile

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gliclazide (Primary) ; Perindopril/indapamide (Primary) ; Antihyperglycaemics
  • Indications Cardiovascular disorders; Diabetic angiopathies; Diabetic complications; Diabetic retinopathy; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ADVANCE-ON
  • Most Recent Events

    • 13 Jul 2019 Results of post hoc analysis assessing benefits of using eGFR slopes for prediction of major clinical outcomes in diabetes using data from ADVANCE and ADVANCE-ON trials published in the Diabetologia
    • 09 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jan 2014 United Kingdom Clinical Research Network reports planned end date as 1 April 2014.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top